Use of NK-1 receptor antagonist serlopitant in pruritus
Inventors
Zhang, Xiaoming • Schnipper, Edward F. • Perlman, Andrew J. • Larrick, James W.
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11026920-B2
Publication Date
2021-06-08
Expiration Date
Abstract
The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.
Core Innovation
A method is described for ameliorating or treating a pruritus-associated condition by administering a therapeutically effective amount of serlopitant or a pharmaceutically acceptable salt, solvate or polymorph thereof to a patient in need of treatment. The condition is a viral infection, thereby positioning serlopitant as an NK-1 receptor antagonist approach for pruritus associated with viral infection.
The described approach includes dosing serlopitant in a therapeutically effective dosage range and specifying administration schedules such as once a day, once every other day, once every third day, once every fourth day, or once per week, with treatment duration of at least 2 weeks, 1 month, 1.5 months, or 2 months. The viral infection is further limited to HIV/AIDS, herpes, measles, a parvovirus, herpes zoster, parvovirus B19, varicella, or yellow fever.
In additional described embodiments, serlopitant administration is combined with other therapies in relation to the viral infection, including administering an antiviral and/or ultraviolet B phototherapy. Further, serlopitant is administered together with a corticosteroid, with serlopitant and the corticosteroid given one, two, three or more times per day and the corticosteroid administered concurrently with or sequentially (before or after) administration of serlopitant.
Claims Coverage
The provided independent claims are two: clm-00001 and clm-00020. The claims center on serlopitant administration for pruritus associated with a viral infection, with one claim focused on serlopitant alone and one on serlopitant in combination with a corticosteroid, including dosing and administration timing features.
Serlopitant for pruritus-associated viral infection
Administering a therapeutically effective amount of serlopitant or a pharmaceutically acceptable salt, solvate or polymorph thereof to a patient in need of treatment, wherein the pruritus-associated condition is a viral infection.
Serlopitant with a corticosteroid for viral infection
Administering a therapeutically effective amount of serlopitant and a corticosteroid to a patient with a viral infection in need of treatment, wherein serlopitant and the corticosteroid are administered one, two, three or more times per day, the corticosteroid is administered concurrently with or sequentially (before or after) administration of serlopitant, and serlopitant includes a loading dose versus maintenance dose relationship.
Across the independent claims, the core coverage centers on using serlopitant for treating pruritus-associated conditions when the condition is a viral infection, including combination administration with a corticosteroid and multi-times-per-day dosing.
Stated Advantages
Documented Applications
No documented applications found
Interested in licensing this patent?